People: EntreMed Inc (ENMD.PH)

ENMD.PH on Philadelphia Stock Exchange

2.20USD
11 Feb 2013
Price Change (% chg)

$-0.23 (-9.47%)
Prev Close
$2.43
Open
$2.20
Day's High
$2.20
Day's Low
$2.20
Volume
200
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Wei-Wu He

 2012 Executive Chairman of the Board

Ken Ren

 2013 Chief Executive Officer

Dwight Bush

 2010 Independent Vice Chairman of the Board

Wong Hu

 42 2008 Chief Operating Officer, General Counsel, Secretary

Sara Capitelli

 45 2011 Vice President - Finance, Principal Accounting Officer

William Gannon

 2012 Vice President - Medical and Regulatory Affairs

Tak Mak

 65 2012 Director

James Huang

 2013 Independent Director

Jennie Hunter-Cevera

 64 2001 Independent Director

Y. Alexander Wu

 2013 Independent Director
» Insider Trading

Biographies

Name Description

Wei-Wu He

 Dr. Wei-Wu He, Ph.D., is Executive Chairman of the Board of Entremed Inc., since February 2, 2012. Dr. He has served as the Chief Executive Officer and Chairman of OriGene Technologies, Inc. since 1995. He also is the founder and General Partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. From 1993 to 1996, Dr. He was a senior scientist at Human Genome Sciences. Prior to that he was a Research Fellow at Massachusetts General Hospital and at the Mayo Clinic. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.

Ken Ren

 Dr. Ken K. Ren has been appointed as Chief Executive Officer of Entremed Inc., effective April 5, 2013. He was formerly the President of the Chinese subsidiary of Accelovance, Inc, a contract research organization offering new drug development solutions to global pharmaceutical and biotech companies. He has served as President of Accelovance since 2005. From 1999-2004, Dr. Ren was the founder and chief executive officer of AHT Pharmaceuticals, Inc. Dr. Ren was a research scientist at Pfizer from 1993 to 1995 and a Research Fellow at the Rockefeller University from 1990 to 1993. Dr. Ren received his Medical degree in China in 1986 and Ph.D. from State University of New York at Buffalo in 1990.

Dwight Bush

 Mr. Dwight L. Bush serves as an Independent Vice Chairman of the Board of Entremed Inc., since January 2010. Mr. Bush has been a Director of the Company since June 2004 and was appointed Vice Chairman in January 2010. Mr. Bush is currently President of D.L. Bush & Associates, a Washington, DC-based financial advisory and business consulting firm. Mr. Bush was previously President & CEO of Urban Trust Bank, Urban Trust Holdings and President of UTB Education Finance, LLC from 2006 through 2008. From 2002-2006, Mr. Bush served in capacities as a principal at Stuart Mill Capital, an Arlington-based investment firm, and as a private investor, and prior to that served in various financial and management roles in financial institutions, including Chase Manhattan Bank and Sallie Mae. Mr. Bush currently serves on the Board of Trustees of The GAVI Alliance and Xavier University of New Orleans and is an Emeritus Trustee of Cornell University. Mr. Bush has 30 years of banking, financial analysis and accounting experience. He is the Chair of the Audit Committee.

Wong Hu

 Ms. Cynthia Wong Hu, J.D., is Chief Operating Officer, General Counsel, Secretary of Entremed Inc. Ms. Hu joined Entremed in June 2006 as Vice President, General Counsel & Secretary and was appointed Chief Operating Officer in December 2008. Prior to joining Entremed, from January 2000 to May 2006, Ms. Hu served as senior attorney for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, Ms. Hu served as counsel for ING Annuities (formerly Golden American Life Insurance Company) and an attorney with the law firms of Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on corporate transactions and compliance with corporate and securities laws.

Sara Capitelli

 Ms. Sara B. Capitelli, CPA, is Vice President - Finance, Principal Accounting Officer of Entremed Inc., since January 10, 2011. Prior to joining the Company, from May 2010 to January 2011, Ms. Capitelli served as Controller for the Association for Financial Professionals in Bethesda, Maryland. From 1999-2008, Ms. Capitelli served as Senior Manager with Ernst & Young LLP, where she provided audit and consulting services for public and private companies. Prior to that, she served as Director, Financial Planning and Reporting of Cable & Wireless USA, a wholly-owned subsidiary of Cable & Wireless plc. Ms. Capitelli holds a CPA license in both Maryland and Virginia. Ms. Capitelli received her Bachelor of Science, Business Administration – Accounting, from Bucknell University.

William Gannon

 Dr. William E. Gannon Jr., M.D., MBA, has been appointed as Vice President - Medical and Regulatory Affairs of EntreMed, Inc., effective May 22, 2012. Dr. Gannon has had over 20 years of experience in the healthcare and pharmaceutical industries. He works in new drug clinical development, regulatory submissions, approvals and commercialization, and has led over 20 submissions of investigational new drug (IND) and/or new drug applications (NDA) with FDA. He also has hands-on experience with European, Canadian and Japanese regulatory environments. Dr. Gannon received a MD degree from Ross University, School of Medicine in New Jersey and a MBA from the George Washington University, Washington, DC.

Tak Mak

 Dr. Tak W. Mak, Ph.D., is Director of Entremed Inc., since February 2, 2012. He has been the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a University Professor in the Department of Medical Biophysics and Department of Immunology, University of Toronto, since 2003. Dr. Mak’s career includes serving as Vice President of Research at Amgen, Inc. and Director of the Amgen Institute in Toronto from 1993-2002, and is known as the scientist of the group that first cloned the genes of the human T cell antigen receptor. r. Mak is an Officer of the Order of Canada, and has been elected a Foreign Associate of the National Academy of Sciences (USA), a Foreign Associate of the American Academy of Arts and Sciences, as well as a Fellow of the Royal Society of London (UK). He was awarded the Order of Ontario and has won international recognition in the form of the Emil von Behring Prize, the King Faisal Prize for Medicine, the Gairdner Foundation International Award, the Sloan Prize of the General Motors Cancer Foundation, the Novartis Prize in Immunology and the Paul Ehrlich Prize and Ludwig Darmstaedter Prize of Germany.

James Huang

 Mr. James Z. Huang has been appointed as Independent Director of EntreMed, Inc., effective April 4, 2013. Mr. Huang is managing partner of Kleiner Perkins Caufield Byers China and general partner of KPCB China Fund II, LP, which invested in the Company’s previously announced registered direct financing that closed in March 2013. Prior to Kleiner Perkins, Mr. Huang was managing partner at Vivo Ventures LLC, a venture capital firm specializing in life science investments. Mr. Huang has over 20 years of experience in the pharmaceutical and biopharmaceutical industry. During this time, he has held senior roles in business development, sales, marketing and R&D with Anesiva, Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkley.

Jennie Hunter-Cevera

 Dr. Jennie C. Hunter-Cevera, PhD., is an Independent Director of Entremed Inc., since June 18, 2001. Dr. Hunter-Cevera is currently the Executive Vice President for Discovery and Analytical Sciences, Government Affairs & Corporate Development, Public Relations and Corporate Communications at RTI International in Durham, NC. She recently chaired the NAS standing committee on translational medicine. From 1999 to July 2009, Dr. Hunter-Cevera was the President of the University of Maryland Biotechnology Institute and from November 1994 to October 1999 was the head of the Center for Environmental Biotechnology at Lawrence Berkeley National Laboratory. She was co-founder of The Biotic Network and Blue Sky Laboratories in Sonora, CA. Dr. Hunter-Cevera was elected to the American Academy of Microbiology in 1995, the recipient of the 1996 SIM Charles Porter Award, elected as a Society for Industrial Microbiology Fellow in 1997, 1999 Nath Lecturer at West Virginia University, and recipient of the WVU Distinguished Alumni in 2004. She is the 2004 recipient of the ASM Porter Award for achievement in biodiversity research and was elected as an AAAS fellow in 2007. She is the Chair of Nominating and Corporate Governance Committee as well as member of Compensation Committee and Audit Committee.

Y. Alexander Wu

 Dr. Y. Alexander Wu, Ph.D., has been appointed as Independent Director of EntreMed, Inc., effective April 4, 2013. Dr. Wu is co-founder and CEO of Crown Bioscience, Inc., a clinical research organization in the oncology space with over 300 employees. Before co-founding Crown Bioscience, Alex was chief business officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the Head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was chief operating officer of Unimicro Technologies, a life science instrumentation company. Dr. Wu started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in Biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley.

Basic Compensation

Name Fiscal Year Total

Wei-Wu He

 --

Ken Ren

 --

Dwight Bush

 --

Wong Hu

 445,938

Sara Capitelli

 --

William Gannon

 --

Tak Mak

 --

James Huang

 --

Jennie Hunter-Cevera

 --

Y. Alexander Wu

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Wei-Wu He

 0 0

Ken Ren

 0 0

Dwight Bush

 0 0

Wong Hu

 0 0

Sara Capitelli

 0 0

William Gannon

 0 0

Tak Mak

 0 0

James Huang

 0 0

Jennie Hunter-Cevera

 0 0

Y. Alexander Wu

 0 0

Insider Trading

Name Shares Traded Price

MAK TAK W

 352,857 $0.00

HE WEI WU

 441,072 $0.00

WONG CYNTHIA

 74,982 $0.00

BUSH DWIGHT L

 2,871 $0.00
» Full list on Insider Trading
Search Stocks